• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Otolaryngologists See Immunotherapy as Hope for Patients with Head and Neck Cancer

by Nikki Kean • February 6, 2020

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

That’s certainly the case with schwannomas and meningiomas caused by neurofibromatosis type 2 (NF2), a rare tumor suppressor syndrome, according to D. Bradley Welling, MD, PhD, who helped discover the genetic mechanisms of the rare disorder.

You Might Also Like

  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • Researchers Find Strong Association Between TERT Antigens and Elevated B Cells in Head and Neck Cancer
  • Post-Treatment Persistence of Oral HPV in Head and Neck Cancer Predicts Recurrence, Death
Explore This Issue
February 2020

Dr. Welling, Walter Augustus Lecompte Professor and chair of Harvard’s department of otolaryngology–head and neck surgery in Boston, pointed to a spinal muscular atrophy type 1 (SMA1) trial that yielded “remarkable, life-altering results” (N Engl J Med. 2017;377:1713-1722).

Patients with SMA1 fail to achieve key motor milestones and often need mechanical ventilation by two years of age. The disorder is caused by a mutation in the survival motor neuron 1 (SMN1) gene, which codes for SMN, a protein necessary for motor neuron function. The rare mutation is fatal in about 90% of patients by 10 months of age, Dr. Welling noted.

In the SMA1 study, 15 patients were given a single low- or high-dose infusion of a viral vector containing DNA aimed at replacing the SMN1 gene. By the end of the study, all 15 patients were alive and event free at 20 months of age, compared with an 8% survival rate in a historical cohort, reported the investigators, from Nationwide Children’s Hospital and The Ohio State University, both in Columbus.

The most impressive results were seen in 12 patients given the high-dose regimen: 11 sat unassisted, nine rolled over, 11 fed orally and could speak, and two were able to walk independently. Dr. Welling noted that in a follow-up study of 100 infants, two infants died, and the researchers reported gains in motor function in other infants (ClinicalTrials.gov Identifier: NCT03306277).

In May 2019, the FDA approved the gene therapy (onasemnogene abeparvovec-xioi; Zolgensma, AveXis) in children with SMA.

Asked why the SMA1 study resonated so much with him, Dr. Welling replied, “It is because of the researchers’ success in transporting a gene into the central nervous system. This is exactly what we hope to achieve for our NF2 patients.”

The stakes are high for success, he stressed. “NF2 shortens the lifespan of those affected and has profound effects on quality of life, resulting in facial paralysis, hearing loss, inability to communicate, disequilibrium, and spinal cord tumors that may cause aspiration and other potentially life-threatening problems,” Dr. Welling explained. “So, it’s a very important condition for us to overcome, and certainly part of the reason why these tumors have been such a strong focus of our research through the years.”

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Head and Neck Tagged With: clinical care, head and neck cancerIssue: February 2020

You Might Also Like:

  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • New Immunotherapy Improves Survival Rates in Squamous Cell Carcinoma of the Head and Neck
  • Researchers Find Strong Association Between TERT Antigens and Elevated B Cells in Head and Neck Cancer
  • Post-Treatment Persistence of Oral HPV in Head and Neck Cancer Predicts Recurrence, Death

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • A Journey Through Pay Inequity: A Physician’s Firsthand Account

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Shifting the Treatment Goalpost Toward Medical Management of Recurrent Respiratory Papillomatosis

    • Excitement Around Gene Therapy for Hearing Restoration

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939